Tocagen (NASDAQ:TOCA) Stock Rating Reaffirmed by Chardan Capital

Chardan Capital restated their hold rating on shares of Tocagen (NASDAQ:TOCA) in a research note released on Wednesday, AnalystRatings.com reports. The brokerage currently has a $1.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the stock. Robert W. Baird cut shares of Tocagen from an outperform rating to a neutral rating in a report on Thursday, September 12th. Cantor Fitzgerald restated a neutral rating on shares of Tocagen in a report on Thursday, October 17th. Zacks Investment Research upgraded shares of Tocagen from a hold rating to a buy rating and set a $1.00 target price on the stock in a report on Wednesday, September 18th. B. Riley cut shares of Tocagen from a buy rating to a neutral rating in a report on Thursday, September 12th. Finally, ValuEngine upgraded shares of Tocagen from a hold rating to a buy rating in a report on Thursday, August 1st. Nine analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $10.23.

TOCA stock traded down $0.01 during trading on Wednesday, reaching $0.59. The company had a trading volume of 130,900 shares, compared to its average volume of 267,089. The company has a market cap of $14.36 million, a P/E ratio of -0.24 and a beta of 3.89. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.43 and a quick ratio of 4.21. The business has a 50 day moving average of $0.63 and a 200 day moving average of $4.23. Tocagen has a 52 week low of $0.53 and a 52 week high of $14.75.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.10). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative net margin of 201,488.91% and a negative return on equity of 182.15%. Research analysts expect that Tocagen will post -2.58 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of TOCA. Dowling & Yahnke LLC boosted its holdings in Tocagen by 41.2% in the second quarter. Dowling & Yahnke LLC now owns 17,122 shares of the company’s stock worth $114,000 after purchasing an additional 5,000 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tocagen during the 2nd quarter worth $551,000. Wells Fargo & Company MN boosted its stake in shares of Tocagen by 60.1% during the 2nd quarter. Wells Fargo & Company MN now owns 53,651 shares of the company’s stock worth $359,000 after acquiring an additional 20,138 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Tocagen by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,684 shares of the company’s stock worth $3,074,000 after acquiring an additional 23,293 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Tocagen by 151.0% during the 2nd quarter. Acadian Asset Management LLC now owns 92,450 shares of the company’s stock worth $618,000 after acquiring an additional 55,621 shares during the last quarter. Institutional investors own 35.20% of the company’s stock.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Story: What is meant by holder of record?

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.